Arcadia Biosciences Inc risk profile
51 Elevated one input has moved against it
Measured 1 September 2026 from RKDA's filed statements. Recomputed nightly.
51 (Elevated), driven by Competitive position at 83, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 81 | Acute | Volatile | One-year price volatility — 110.1% |
| Operating pressure | 5 | Contained | Easing | Input-cost exposure — 0.11 |
| Cash conversion | 57 | Elevated | Easing | Free-cash-flow margin — -96.7% |
| Leverage and coverage | 6 | Contained | Stable | Current ratio — 3.09x |
| Competitive position | 83 | Acute | Stable | Operating-margin gap against peers — -34.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Consumer Defensive companies with a risk reading
Walmart Inc 43Costco Wholesale Corp 40Coca-Cola Company 30Procter & Gamble Company 34Philip Morris International Inc 24Nestle S.A. 45Nestlé S.A 45L'Oréal S.A. 32PepsiCo Inc 43Anheuser-Busch InBev SA/NV 35Unilever plc 42Unilever PLC 42
Financials, valuation and price history for Arcadia Biosciences Inc